P3373
Women's preferences regarding infant or maternal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV during breastfeeding and their views on Option B+ in Dar es Salaam, TanzaniaThe potential of task-shifting in scaling up services for prevention of mother-to-child transmission of HIV: a time and motion study in Dar es Salaam, Tanzania.Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania.Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.Incidence of HIV and the prevalence of HIV, hepatitis B and syphilis among youths in Maputo, Mozambique: a cohort studyVirologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, TanzaniaPotent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.Innate immunity in experimental SIV infection and vaccination.Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.Predictors of Patient Dissatisfaction with Services for Prevention of Mother-To-Child Transmission of HIV in Dar es Salaam, Tanzania.Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunityBroad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998 1999.Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.Nonvertical, nonsexual transmission of human immunodeficiency virus in children.Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.HIV-1 infection prevalence and incidence trends in areas of contrasting levels of infection in the Kagera region, Tanzania, 1987-2000.Job satisfaction and turnover intentions among health care staff providing services for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania.Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study.Slow progression of HIV-1 infection in a cohort of antiretroviral naïve hotel workers in Dar es Salaam, Tanzania as defined by their CD4 cell slopes.Evaluation of HIV antibody and antigen/antibody combination ELISAs for use in an alternative confirmatory HIV testing strategy in Dar es Salaam, Tanzania.Mortality during the first 24 months after delivery in relation to CD4 T-lymphocyte levels and viral load in a cohort of breast-feeding HIV-1-infected women in Dar es Salaam, Tanzania.The natural course of disease following HIV-1 infection in dar es salaam, Tanzania: a study among hotel workers relating clinical events to CD4 T-lymphocyte counts.Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania.The prevalence and pattern of skin diseases in relation to CD4 counts among HIV-infected police officers in Dar es Salaam.Evaluation of an alternative confirmatory strategy for the diagnosis of HIV infection in Dar Es Salaam, Tanzania, based on simple rapid assays.Clinical progression in early and late stages of disease in a cohort of individuals infected with human immunodeficiency virus-2 in Guinea-Bissau.Treatment of Kaposi sarcoma in human immunodeficiency virus-1-infected Mozambican children with antiretroviral drugs and chemotherapy.Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.Comparison of the performance of rapid HIV tests using samples collected for surveillance in Mozambique.High sexual risk taking and diverging trends of HIV-1 and HIV-2 in the military of Guinea Bissau.A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry.Dichotomy between CD1a+ and CD83+ dendritic cells in lymph nodes during SIV infection of macaques.A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice
P50
Q28538970-4B1C1336-B7D6-4FA9-9DF7-E3423531D494Q33733664-2661D843-8E4C-487D-820A-B4026CEFCE01Q33962664-E48D3DF1-8360-4A4A-96DE-4828D2A15123Q34707535-9F957AF6-63BE-4C84-AAB7-298BB0D81B1EQ35077438-DB62D012-84E4-460F-9343-BD19166CECD6Q35208491-2AFB619B-D235-4CEB-A052-7C8EA0977A5BQ35357751-C763073E-5CBD-451C-A797-59916F9DD578Q35415717-61F70531-BBF1-404E-8F42-CB0B52A7E1D7Q35431516-B20CE0E2-8F9F-4732-BB95-961BEB16500CQ35677513-239B79A8-238E-48C0-956D-FCCA0D70CA1EQ35920257-C15F83F6-07A7-4082-B201-FC9E80DFAF39Q36021144-9F21FF91-8254-487C-8254-B971BAA984CFQ36170807-D8B7767A-F3C8-43C4-8E0A-226F8A65A60BQ36679394-7FF74B62-E1A9-42DA-9E10-14F9A90582AEQ36692389-3B81FC1A-D93D-49C2-A08F-98ADD8867009Q36697992-C594CAC5-7D72-4845-85F3-8A7F7CA45C52Q37006418-2913D0DC-F07C-415C-AF79-0FED3A4BCFEBQ37610683-7517A552-ADCC-41D4-8D64-FB8338FEC7A1Q37657010-4CE0A2ED-B11E-4725-99ED-C5D007F2826DQ38897238-3C51B316-46E5-486B-A96F-B7296431BD79Q39736082-51EB53A4-9205-4DFD-920C-25ED55449EBBQ40066180-9BFDCC80-ED3D-4884-BD5C-2669AAF8587EQ40393896-E0FDEBB6-4103-48E2-A5AC-EE54D4EE95C5Q43281055-EC5D83E1-BA82-4DA2-A2DD-8B14143AB821Q43944707-5DCA2A1C-D04B-4091-A232-ABF7E094989FQ43945251-F78C5169-9676-4194-8E46-3ECB89E5D96EQ43946932-5EED26E7-BE4F-45DF-AA7F-DB8E56765367Q43948087-C55D5581-CBEF-4FD5-B567-709B53EEAF17Q43948596-90B20FB5-85C5-491D-929B-0CA29BF1C8D9Q43948839-0E743B14-CAE3-412B-A4A5-B4B0764EBFEDQ43949755-FCCF9A54-CB19-41B5-82AF-5594F83840BAQ43950654-3AE580B2-13CB-4C9A-A71C-0C5353DB0374Q44430005-8BE96A24-135B-4730-8D9C-AF7F579E6D19Q45365209-85C1DE5F-054E-4722-8C2F-B39D5A354963Q45733231-63F8A781-ABA0-4892-8FEE-69F4904FC157Q46176862-ECAD8AE1-9D95-4DD3-B8BD-544804473FFCQ46271099-6F3E6FF9-C41A-45B2-BCE3-6FE4467634D4Q46756238-B8577D9F-10E1-4E7E-BFB4-AD34694291F4Q47828743-BE6850A6-CB93-4E2F-8DBF-F566B235A311Q58682308-FA410C73-37D8-4896-B8CB-C46847AC7138
P50
description
associated professor at Karolinska Institutet
@en
läkare: medicinsk mikrobiologi
@sv
name
Gunnel Biberfeld
@ast
Gunnel Biberfeld
@ca
Gunnel Biberfeld
@da
Gunnel Biberfeld
@de
Gunnel Biberfeld
@ee
Gunnel Biberfeld
@en
Gunnel Biberfeld
@es
Gunnel Biberfeld
@fi
Gunnel Biberfeld
@fr
Gunnel Biberfeld
@ga
type
label
Gunnel Biberfeld
@ast
Gunnel Biberfeld
@ca
Gunnel Biberfeld
@da
Gunnel Biberfeld
@de
Gunnel Biberfeld
@ee
Gunnel Biberfeld
@en
Gunnel Biberfeld
@es
Gunnel Biberfeld
@fi
Gunnel Biberfeld
@fr
Gunnel Biberfeld
@ga
altLabel
Inez Gunnel Biberfeld
@sv
Inez Gunnel Wickström
@sv
prefLabel
Gunnel Biberfeld
@ast
Gunnel Biberfeld
@ca
Gunnel Biberfeld
@da
Gunnel Biberfeld
@de
Gunnel Biberfeld
@ee
Gunnel Biberfeld
@en
Gunnel Biberfeld
@es
Gunnel Biberfeld
@fi
Gunnel Biberfeld
@fr
Gunnel Biberfeld
@ga
P1006
P214
P5587
P906
P1006
P21
P213
0000 0000 5318 2064
P214
P27
P31
P3373
P5587
20dgg6ml22gmkn3
P569
1936-11-19T00:00:00Z
P735
P7859
viaf-41809647